Moderna announced compelling phase 3 results for its mRNA-1010 influenza vaccine, demonstrating 26.6% improved efficacy over a licensed standard-dose comparator in adults 50 years and older. The vaccine showed effectiveness against all included strains, including A/H1N1 and B/Victoria lineages. Safety profiles remained consistent with prior studies. The data support upcoming regulatory submissions, advancing Moderna’s flu vaccine program alongside ambitions for combined flu-COVID shots.